The latest price target for Vera Therapeutics (NASDAQ:VERA) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $107.00 expecting VERA to rise to within 12 months (a possible 150.12% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Vera Therapeutics (NASDAQ:VERA) was provided by Cantor Fitzgerald, and Vera Therapeutics reiterated their overweight rating.

The last upgrade for Vera Therapeutics Inc happened on January 26, 2024 when Raymond James raised their price target to $37. Raymond James previously had an outperform for Vera Therapeutics Inc.

The last downgrade for Vera Therapeutics Inc happened on January 4, 2023 when Jefferies changed their price target from $32 to $6 for Vera Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vera Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Vera Therapeutics (VERA) rating was a reiterated with a price target of $107.00 to $107.00. The current price Vera Therapeutics (VERA) is trading at is $42.78, which is out of the analyst’s predicted range.